Conditions: Polycystic Ovary Syndrome Cardiovascular Disease
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 72
Healthy volunteers: no

Brief summary:
Polycystic ovary syndrome (PCOS) affects 5-10% of women in fertile age. PCOS is associated with metabolic syndrom, diabetes and and increased risk og cardiovascular disease.

The study investigates the effect af intervention with GLP-1-analog on risk markers of cardiovascular disease in women with PCOS.

70 women will be included in af RCT.

Hypothesis: GLP-1-analog treatment in women with PCOS (without diabetes) will result in a beneficial reduction in risk markers of vascular thrombosis and early cardiovascular disease.

Detailed description:

Arms:
arm 1: Liraglutide s.c. 1,8mg daily for 26 weeks arm 2: Placebo s.c. daily for 26 weeks

Interventions: intervention 1: Liraglutide for 26 weeks intervention 2: placebo
Intervention descriptions: intervention 1: GLP-1-analogue Liraglutide s.c. 1,8mg daily for 26 weeks intervention 2: Placebo s.c. daily for 26 weeks

Protocol document: